Victor I Reus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6316373/publications.pdf

Version: 2024-02-01

226 papers 15,682 citations

64 h-index 19190 118 g-index

341 all docs

341 docs citations

times ranked

341

17448 citing authors

#	Article	IF	CITATIONS
1	Genome-wide mapping of brain phenotypes in extended pedigrees with strong genetic loading for bipolar disorder. Molecular Psychiatry, 2021, 26, 5229-5238.	7.9	4
2	Genetic analysis of activity, brain and behavioral associations in extended families with heavy genetic loading for bipolar disorder. Psychological Medicine, 2021, 51, 494-502.	4.5	6
3	Utilization of machine learning for identifying symptom severity military-related PTSD subtypes and their biological correlates. Translational Psychiatry, 2021, 11 , 227.	4.8	11
4	"GrimAge,―an epigenetic predictor of mortality, is accelerated in major depressive disorder. Translational Psychiatry, 2021, 11, 193.	4.8	46
5	Serum brain-derived neurotrophic factor remains elevated after long term follow-up of combat veterans with chronic post-traumatic stress disorder. Psychoneuroendocrinology, 2021, 134, 105360.	2.7	6
6	Abnormal levels of mitochondrial proteins in plasma neuronal extracellular vesicles in major depressive disorder. Molecular Psychiatry, 2021, 26, 7355-7362.	7.9	36
7	Pre-treatment allostatic load and metabolic dysregulation predict SSRI response in major depressive disorder: a preliminary report. Psychological Medicine, 2021, 51, 2117-2125.	4.5	16
8	Development and Implementation of a Chief Resident for Research Role in a Psychiatry Residency Training Program. Advances in Medical Education and Practice, 2021, Volume 12, 1231-1236.	1.5	1
9	Blood-based mitochondrial respiratory chain function in major depression. Translational Psychiatry, 2021, 11, 593.	4.8	11
10	Multi-omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder. Molecular Psychiatry, 2020, 25, 3337-3349.	7.9	68
11	The DSM-5 Clinical and Public Health Committee (CPHC): operations, mechanics, controversies and recommendations. Psychological Medicine, 2020, 51, 1-8.	4.5	1
12	Vitamin D and inflammation in major depressive disorder. Journal of Affective Disorders, 2020, 267, 33-41.	4.1	21
13	Distinct and shared contributions of diagnosis and symptom domains to cognitive performance in severe mental illness in the Paisa population: a case-control study. Lancet Psychiatry, the, 2020, 7, 411-419.	7.4	24
14	Contribution of common and rare variants to bipolar disorder susceptibility in extended pedigrees from population isolates. Translational Psychiatry, 2020, 10, 74.	4.8	25
15	Effect of Combat Exposure and Posttraumatic Stress Disorder on Telomere Length and Amygdala Volume. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 678-687.	1.5	10
16	Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis. Psychoneuroendocrinology, 2019, 109, 104386.	2.7	11
17	Psychiatric manifestations of neurologic diseases: Etiology, phenomenology, and treatment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 1-4.	1.8	1
18	Metabolomic analysis of male combat veterans with post traumatic stress disorder. PLoS ONE, 2019, 14, e0213839.	2. 5	54

#	Article	IF	Citations
19	Accelerated aging in serious mental disorders. Current Opinion in Psychiatry, 2019, 32, 381-387.	6.3	30
20	Low serum brain-derived neurotrophic factor is associated with suicidal ideation in major depressive disorder. Psychiatry Research, 2019, 273, 108-113.	3.3	29
21	Shared Genetics of Psychiatric Disorders. F1000Research, 2019, 8, 1626.	1.6	8
22	F174. Higher Baseline Plasma Serotonin, and a Greater Decrease in Serotonin Over Treatment, is Associated With Better SSRI Response in MDD. Biological Psychiatry, 2018, 83, S306.	1.3	1
23	62. Circulating Cell-Free Mitochondrial DNA – a Novel Marker of Mitochondrial Stress Associated With Suicidality and Major Depressive Disorder. Biological Psychiatry, 2018, 83, S25-S26.	1.3	1
24	Circulating cell-free mitochondrial DNA, but not leukocyte mitochondrial DNA copy number, is elevated in major depressive disorder. Neuropsychopharmacology, 2018, 43, 1557-1564.	5.4	135
25	The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. American Journal of Psychiatry, 2018, 175, 86-90.	7.2	202
26	Predisposition to Neuropsychiatric Disease: Common Genetic Risk Factors. Focus (American) Tj ETQq0 0 0 rgBT	/Overlock	10 ₁ Tf 50 462
27	Understanding the Hidden Complexity of Latin American Population Isolates. American Journal of Human Genetics, 2018, 103, 707-726.	6.2	48
28	233. Indices of Cellular Health are Associated With Antidepressant Treatment Response. Biological Psychiatry, 2018, 83, S93-S94.	1.3	0
29	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
30	The Role of Regional Conferences in Research Resident Career Development: The California Psychiatry Research Resident Retreat. Academic Psychiatry, 2017, 41, 272-277.	0.9	5
31	Severity of anxiety– but not depression– is associated with oxidative stress in Major Depressive Disorder. Journal of Affective Disorders, 2017, 219, 193-200.	4.1	42
32	1005. Pre-Treatment Allostatic Load and Metabolic Dysregulation Predict Antidepressant Response in Major Depressive Disorder. Biological Psychiatry, 2017, 81, S406-S407.	1.3	0
33	Biological predictors of insulin resistance associated with posttraumatic stress disorder in young military veterans. Psychoneuroendocrinology, 2017, 82, 91-97.	2.7	44
34	709. Increased Circulating Blood Cell Counts in Combat-Related PTSD: Associations with Inflammation and Symptom Severity. Biological Psychiatry, 2017, 81, S287-S288.	1.3	0
35	Oxidative stress, inflammation and treatment response in major depression. Psychoneuroendocrinology, 2017, 76, 197-205.	2.7	332
36	Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression. Psychoneuroendocrinology, 2017, 77, 122-130.	2.7	20

#	Article	IF	CITATIONS
37	Increased circulating blood cell counts in combat-related PTSD: Associations with inflammation and PTSD severity. Psychiatry Research, 2017, 258, 330-336.	3.3	41
38	Telomere length is inversely correlated with urinary stress hormone levels in healthy controls but not in un-medicated depressed individuals-preliminary findings. Journal of Psychosomatic Research, 2017, 99, 177-180.	2.6	8
39	Increased pro-inflammatory milieu in combat related PTSD – A new cohort replication study. Brain, Behavior, and Immunity, 2017, 59, 260-264.	4.1	93
40	So Where Are the Genes for Bipolar Disorder?. Focus (American Psychiatric Publishing), 2017, 15, 9s-10s.	0.8	0
41	Characterization of Expression Quantitative Trait Loci in Pedigrees from Colombia and Costa Rica Ascertained for Bipolar Disorder. PLoS Genetics, 2016, 12, e1006046.	3.5	4
42	A population of atypical CD56â^'CD16+ natural killer cells is expanded in PTSD and is associated with symptom severity. Brain, Behavior, and Immunity, 2016, 56, 264-270.	4.1	25
43	The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. American Journal of Psychiatry, 2016, 173, 543-546.	7.2	279
44	Cortisol/DHEA ratio and hippocampal volume: A pilot study in major depression and healthy controls. Psychoneuroendocrinology, 2016, 72, 139-146.	2.7	29
45	Leukocyte Telomere Length Predicts SSRI Response in Major Depressive Disorder: A Preliminary Report. Molecular Neuropsychiatry, 2016, 2, 88-96.	2.9	32
46	Genetic contributions to circadian activity rhythm and sleep pattern phenotypes in pedigrees segregating for severe bipolar disorder. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E754-61.	7.1	77
47	Global arginine bioavailability, a marker of nitric oxide synthetic capacity, is decreased in PTSD and correlated with symptom severity and markers of inflammation. Brain, Behavior, and Immunity, 2016, 52, 153-160.	4.1	65
48	Association of dimensional psychological health measures with telomere length in male war veterans. Journal of Affective Disorders, 2016, 190, 537-542.	4.1	38
49	Mitochondrial DNA copy number is reduced in male combat veterans with PTSD. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 10-17.	4.8	73
50	Telomere length is inversely correlated with urinary stress hormone levels in healthy controls but not in un-medicated depressed individuals – Preliminary findings. Psychoneuroendocrinology, 2015, 61, 61.	2.7	0
51	Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging. Neuroscience and Biobehavioral Reviews, 2015, 55, 333-364.	6.1	264
52	PBMC telomerase activity, but not leukocyte telomere length, correlates with hippocampal volume in major depression. Psychiatry Research - Neuroimaging, 2015, 232, 58-64.	1.8	33
53	Smoking cessation abstinence goal in treatment-seeking smokers. Addictive Behaviors, 2015, 42, 148-153.	3.0	10
54	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. American Journal of Psychiatry, 2015, 172, 82-93.	7.2	117

#	Article	IF	Citations
55	Involvement of astrocyte metabolic coupling in Tourette syndrome pathogenesis. European Journal of Human Genetics, 2015, 23, 1519-1522.	2.8	22
56	Brain structure–function associations in multi-generational families genetically enriched for bipolar disorder. Brain, 2015, 138, 2087-2102.	7.6	33
57	Telomerase activation as a possible mechanism of action for psychopharmacological interventions. Drug Discovery Today, 2015, 20, 1305-1309.	6.4	48
58	Functional Neurologic Symptom Disorders. , 2014, , 1069-1085.		1
59	Peripheral antioxidant markers are associated with total hippocampal and CA3/dentate gyrus volume in MDD and healthy controls–preliminary findings. Psychiatry Research - Neuroimaging, 2014, 224, 168-174.	1.8	31
60	Multisystem Component Phenotypes of Bipolar Disorder for Genetic Investigations of Extended Pedigrees. JAMA Psychiatry, 2014, 71, 375.	11.0	87
61	Smoking Cessation Outcomes Among Sexual and Gender Minority and Nonminority Smokers in Extended Smoking Treatments. Nicotine and Tobacco Research, 2014, 16, 1207-1215.	2.6	27
62	Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. Brain, Behavior, and Immunity, 2014, 42, 81-88.	4.1	178
63	Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 910-919.	0.5	111
64	Adverse childhood experiences and leukocyte telomere maintenance in depressed and healthy adults. Journal of Affective Disorders, 2014, 169, 86-90.	4.1	51
65	Prevalence and clinical correlates of explosive outbursts in Tourette Syndrome. Psychiatry Research, 2013, 205, 269-275.	3.3	53
66	Genome-wide association study of Tourette's syndrome. Molecular Psychiatry, 2013, 18, 721-728.	7.9	161
67	Dysregulated relationship of inflammation and oxidative stress in major depression. Brain, Behavior, and Immunity, 2013, 31, 143-152.	4.1	199
68	Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. PLoS Genetics, 2013, 9, e1003864.	3.5	241
69	Eleven-Year Outcomes From an Integrated Residency Program to Train Research Psychiatrists. Academic Medicine, 2013, 88, 983-988.	1.6	25
70	CNV Analysis in Tourette Syndrome Implicates Large Genomic Rearrangements in COL8A1 and NRXN1. PLoS ONE, 2013, 8, e59061.	2.5	70
71	Genome-Wide Linkage Analysis of Obsessive-Compulsive Disorder Implicates Chromosome 1p36. Biological Psychiatry, 2012, 72, 629-636.	1.3	36
72	Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Molecular Psychiatry, 2012, 17, 164-172.	7.9	112

#	Article	IF	Citations
73	Cortisol awakening response and cortisol/DHEA ratio associations with hippocampal volume in MDD. HÃ \P gre Utbildning, 2012, 3, .	3.0	2
74	Recent Trends in American Board of Psychiatry and Neurology Psychiatric Subspecialties. Academic Psychiatry, 2011, 35, 35-39.	0.9	31
75	Serum BDNF levels before treatment predict SSRI response in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1623-1630.	4.8	133
76	Leukocyte Telomere Length in Major Depression: Correlations with Chronicity, Inflammation and Oxidative Stress - Preliminary Findings. PLoS ONE, 2011, 6, e17837.	2.5	353
77	Using Extended Cognitive Behavioral Treatment and Medication to Treat Dependent Smokers. American Journal of Public Health, 2011, 101, 2349-2356.	2.7	54
78	Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic. Clinical Pharmacology and Therapeutics, 2011, 89, 392-399.	4.7	172
79	Of sound mind and body: depression, disease, and accelerated aging. Dialogues in Clinical Neuroscience, 2011, 13, 25-39.	3.7	175
80	Depression gets old fast: do stress and depression accelerate cell aging?. Depression and Anxiety, 2010, 27, 327-338.	4.1	242
81	Genome-Wide Linkage Scan of Bipolar Disorder in a Colombian Population Isolate Replicates Loci on Chromosomes 7p21–22, 1p31, 16p12 and 21q21–22 and Identifies a Novel Locus on Chromosome 12q. Human Heredity, 2010, 70, 255-268.	0.8	25
82	Personal Identity and Fractured Selves: Perspectives From Philosophy, Ethics, and Neuroscienceedited by MathewsDebra J.H., BokHilary, and RabinsPeter V. Baltimore, Johns Hopkins University Press, 2009, 216pp., \$55.00 American Journal of Psychiatry, 2010, 167, 1000-1000.	7.2	0
83	Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. Journal of Psychiatric Research, 2009, 43, 962-969.	3.1	171
84	Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Frontiers in Neuroendocrinology, 2009, 30, 65-91.	5.2	600
85	A narrow and highly significant linkage signal for severe bipolar disorder in the chromosome 5q33 region in Latin American pedigrees. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 998-1006.	1.7	5
86	Extended treatment of older cigarette smokers. Addiction, 2009, 104, 1043-1052.	3.3	103
87	Glucocorticoids. Annals of the New York Academy of Sciences, 2009, 1179, 19-40.	3.8	149
88	Longitudinal analysis of abstinence-specific social support and smoking cessation Health Psychology, 2009, 28, 465-472.	1.6	50
89	The ABCB1 transporter gene and antidepressant response. F1000 Biology Reports, 2009, 1, 23.	4.0	13
90	A comparative study of obsessive-compulsive disorder in Costa Rica and the United States. Depression and Anxiety, 2008, 25, 609-619.	4.1	24

#	Article	IF	Citations
91	Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. International Journal of Clinical Practice, 2008, 62, 1753-1768.	1.7	35
92	Therapeutic Drug Monitoring of Nortriptyline in Smoking Cessation: A Multistudy Analysis. Clinical Pharmacology and Therapeutics, 2008, 83, 436-442.	4.7	16
93	The ABPN Maintenance of Certification Program for Psychiatrists: Past History, Current Status, and Future Directions. Academic Psychiatry, 2008, 32, 241-248.	0.9	2
94	Physical activity as a strategy for maintaining tobacco abstinence: A randomized trial. Preventive Medicine, 2008, 47, 215-220.	3.4	87
95	Older versus younger treatment-seeking smokers: Differences in smoking behavior, drug and alcohol use, and psychosocial and physical functioning. Nicotine and Tobacco Research, 2008, 10, 463-470.	2.6	37
96	An Argument for Mindby Jerome Kagan. New Haven, Conn., Yale University Press, 2007, 304 pp., \$27.50 American Journal of Psychiatry, 2008, 165, 922-923.	7.2	0
97	Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. American Journal of Health Behavior, 2008, 32, 664-75.	1.4	62
98	Belief about drug assignment and abstinence in treatment of cigarette smoking using nortriptyline. Nicotine and Tobacco Research, 2007, 9, 467-471.	2.6	9
99	EFFICACY AND SAFETY OF 12 WEEKS OF VARENICLINE OR PLACEBO FOR SMOKING CESSATION: POOLED RESULTS FROM THREE CLINICAL TRIALS. Chest, 2007, 132, 490B.	0.8	1
100	Tic Symptom Profiles in Subjects with Tourette Syndrome from two Genetically Isolated Populations. Biological Psychiatry, 2007, 61, 292-300.	1.3	57
101	Heritability and clinical features of multigenerational families with obsessive-compulsive disorder and hoarding. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 174-182.	1.7	55
102	The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response. Clinical Pharmacology and Therapeutics, 2007, 81, 328-345.	4.7	230
103	Varenicline: New treatment with efficacy in smoking cessation. Drugs of Today, 2007, 43, 65.	1.1	38
104	Results of a SNP genome screen in a large Costa Rican pedigree segregating for severe bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 367-373.	1.7	19
105	Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Human Molecular Genetics, 2006, 15, 3324-3328.	2.9	97
106	Catecholamine Response to Methamphetamine is Related to Glucocorticoid Levels but not to Pleasurable Subjective Response. Pharmacopsychiatry, 2006, 39, 100-108.	3.3	1
107	Convergent linkage evidence from two Latin-American population isolates supports the presence of a susceptibility locus for bipolar disorder in 5q31–34. Human Molecular Genetics, 2006, 15, 3146-3153.	2.9	40
108	Association Between Maternal Smoking and Increased Symptom Severity in Tourette's Syndrome. American Journal of Psychiatry, 2006, 163, 1066-1073.	7.2	77

#	Article	IF	CITATIONS
109	Association Between Maternal Smoking and Increased Symptom Severity in Tourette's Syndrome. American Journal of Psychiatry, 2006, 163, 1066.	7.2	25
110	Bipolar Disorders: Mixed States, Rapid Cycling, and Atypical Forms. Journal of Clinical Psychiatry, 2006, 67, 1823.	2.2	0
111	The American Psychiatric Publishing Textbook of Mood Disorders. American Journal of Psychiatry, 2006, 163, 1844-1845.	7.2	0
112	Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. Journal of Behavioral Health Services and Research, 2005, 32, 381-392.	1.4	48
113	Preliminary evidence of the association between the history of childhood attentionaedeficit/hyperactivity disorder and smoking treatment failure. Nicotine and Tobacco Research, 2005, 7, 453-460.	2.6	80
114	Repeated psychological stress testing in stimulant-dependent patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 669-677.	4.8	30
115	Response to Zhang et al. (2005) Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron 45, 11–16. Neuron, 2005, 48, 704-705.	8.1	27
116	Extended Nortriptyline and Psychological Treatment for Cigarette Smoking. American Journal of Psychiatry, 2004, 161, 2100-2107.	7.2	148
117	Self injurious behaviour in Tourette syndrome: correlates with impulsivity and impulse control. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1149-1155.	1.9	118
118	Hormonal changes with cholesterol reduction: a double-blind pilot study. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 71-73.	1.5	9
119	Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation. Psychoneuroendocrinology, 2004, 29, 486-500.	2.7	33
120	Genetic mapping using haplotype and model-free linkage analysis supports previous evidence for a locus predisposing to severe bipolar disorder at 5q31-33., 2004, 125B, 83-86.		26
121	Why genetic investigation of psychiatric disorders is so difficult. Current Opinion in Genetics and Development, 2004, 14, 280-286.	3.3	45
122	Genetic studies of neuropsychiatric disorders in Costa Rica: a model for the use of isolated populations. Psychiatric Genetics, 2004, 14, 13-23.	1.1	37
123	Influences of Mood, Depression History, and Treatment Modality on Outcomes in Smoking Cessation Journal of Consulting and Clinical Psychology, 2004, 72, 563-570.	2.0	131
124	Neurotransmitters, neurosteroids and neurotrophins: New models of the pathophysiology and treatment of depression. World Journal of Biological Psychiatry, 2003, 4, 98-102.	2.6	22
125	Behavioral Implications of Lowering Cholesterol Levels: A Double-Blind Pilot Study. Psychosomatics, 2003, 44, 412-414.	2.5	35
126	Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part III: Bipolar Disorder. American Journal of Human Genetics, 2003, 73, 49-62.	6.2	400

#	Article	IF	CITATIONS
127	Altering Cortisol Level does not Change the Pleasurable Effects of Methamphetamine in Humans. Neuropsychopharmacology, 2003, 28, 1677-1684.	5.4	31
128	Pharmacogenetics of monoamine transporters. Pharmacogenomics, 2003, 4, 571-582.	1.3	15
129	Genetic Linkage in Bipolar Disorder. CNS Spectrums, 2003, 8, 891-904.	1.2	26
130	Behavior and Mood Disorders in Focal Brain Lesions. American Journal of Psychiatry, 2003, 160, 194-195.	7.2	0
131	Handbook of Diagnostic and Structured Interviewing. Journal of Clinical Psychiatry, 2003, 64, 488.	2.2	0
132	Benzodiazepines in Schizophrenia: Prefrontal Cortex Atrophy Predicts Clinical Response to Alprazolam Augmentation. World Journal of Biological Psychiatry, 2002, 3, 221-224.	2.6	7
133	Double-Blind Antiglucocorticoid Treatment in Schizophrenia and Schizoaffective Disorder: A Pilot Study. World Journal of Biological Psychiatry, 2002, 3, 156-161.	2.6	13
134	Psychological Intervention and Antidepressant Treatment in Smoking Cessation. Archives of General Psychiatry, 2002, 59, 930.	12.3	178
135	Genomewide Linkage Disequilibrium Mapping of Severe Bipolar Disorder in a Population Isolate. American Journal of Human Genetics, 2002, 71, 565-574.	6.2	63
136	Comorbidity of bipolar disorder and substance abuse in Costa Rica: pedigree- and population-based studies. Journal of Affective Disorders, 2002, 71, 71-83.	4.1	14
137	Cortisol levels predict cognitive impairment induced by electroconvulsive therapy. Biological Psychiatry, 2001, 50, 331-336.	1.3	44
138	Genome screening for linkage disequilibrium in a Costa Rican sample of patients with bipolar-I disorder: A follow-up study on chromosome 18. American Journal of Medical Genetics Part A, 2001, 105, 207-213.	2.4	35
139	Assortative mating in the affective disorders: A systematic review and meta-analysis. Comprehensive Psychiatry, 2001, 42, 257-262.	3.1	112
140	Cultural Influences on Diagnosis and Perception of Tourette Syndrome in Costa Rica. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 456-463.	0.5	22
141	Movement Disorder, Memory, Psychiatric Symptoms and Serum DHEA Levels in Schizophrenic and Schizoaffective Patients. World Journal of Biological Psychiatry, 2001, 2, 99-102.	2.6	61
142	Psychoneuroendocrine aspects of treatment-resistant mood disorders., 2001,, 49-79.		0
143	Understanding Troubled Minds: A Guide to Mental Illness and Its Treatment. American Journal of Psychiatry, 2001, 158, 331-b-332.	7.2	0
144	The Balance Within: The Science Connecting Health and Emotions. American Journal of Psychiatry, 2001, 158, 1179-1179.	7.2	0

#	Article	IF	Citations
145	Antiglucocorticoid drugs in the treatment of depression. Expert Opinion on Investigational Drugs, 2001, 10, 1789-1796.	4.1	74
146	Stress Hormone-Related Psychopathology: Pathophysiological and Treatment Implications. World Journal of Biological Psychiatry, 2001, 2, 115-143.	2.6	116
147	Fine-scale mapping of a locus for severe bipolar mood disorder on chromosome 18p11.3 in the Costa Rican population. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11485-11490.	7.1	36
148	Bipolar Medications. Journal of Clinical Psychiatry, 2001, 62, 576-577.	2.2	0
149	Development of Major Depression After Treatment for Smoking Cessation. American Journal of Psychiatry, 2000, 157, 368-374.	7.2	179
150	Dehydroepiandrosterone in aging and mental health., 2000,, 144-167.		1
151	An association study of bipolar mood disorder (type I) with the 5-HTTLPR serotonin transporter polymorphism in a human population isolate from Colombia. Neuroscience Letters, 2000, 292, 199-202.	2.1	78
152	Possible Interaction of Tramadol and Antidepressants. American Journal of Psychiatry, 2000, 157, 839-839.	7.2	14
153	The Role of Dehydroepiandrosterone (DHEA) in Psychiatry. Psychiatric Annals, 2000, 30, 123-128.	0.1	7
154	Bipolar Disorders: Clinical Course and Outcome. American Journal of Psychiatry, 2000, 157, 1187-1188.	7.2	0
155	Depressive Symptoms and Cognitive Decline in Nondemented Elderly Women. Archives of General Psychiatry, 1999, 56, 425.	12.3	366
156	Assessing the Feasibility of Linkage Disequilibrium Methods for Mapping Complex Traits: An Initial Screen for Bipolar Disorder Loci on Chromosome 18. American Journal of Human Genetics, 1999, 64, 1670-1678.	6.2	61
157	History of alcohol or drug problems, current use of alcohol or marijuana, and success in quitting smoking. Addictive Behaviors, 1999, 24, 149-154.	3.0	94
158	Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biological Psychiatry, 1999, 45, 1070-1074.	1.3	160
159	Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biological Psychiatry, 1999, 46, 182-188.	1.3	67
160	Treatment of Depression With Antiglucocorticoid Drugs. Psychosomatic Medicine, 1999, 61, 698-711.	2.0	153
161	Double-Blind Treatment of Major Depression With Dehydroepiandrosterone. American Journal of Psychiatry, 1999, 156, 646-649.	7.2	357
162	Mapping genes for psychiatric disorders and behavioral traits. Current Opinion in Genetics and Development, 1998, 8, 287-292.	3.3	18

#	Article	IF	CITATIONS
163	Cortisol and response to dexamethasone as predictors of withdrawal distress and abstinence success in smokers. Biological Psychiatry, 1998, 43, 525-530.	1.3	78
164	284. Cortisol predicts cognitive impairment induced by electroconvulsive therapy. Biological Psychiatry, 1998, 43, S85.	1.3	0
165	Nortriptyline and Cognitive-Behavioral Therapy in the Treatment of Cigarette Smoking. Archives of General Psychiatry, 1998, 55, 683.	12.3	360
166	Selective Alteration of Personality and Social Behavior by Serotonergic Intervention. American Journal of Psychiatry, 1998, 155, 373-379.	7.2	536
167	Olanzapine: a novel atypical neuroleptic agent. Lancet, The, 1997, 349, 1264-1265.	13.7	51
168	Understanding the Genetic Basis of Mood Disorders: Where Do We Stand?. American Journal of Human Genetics, 1997, 60, 1283-1288.	6.2	42
169	Dehydroepiandrosterone (DHEA) treatment of depression. Biological Psychiatry, 1997, 41, 311-318.	1.3	308
170	Glucocorticoid Medication, Memory and Steroid Psychosis in Medical Illness. Annals of the New York Academy of Sciences, 1997, 823, 81-96.	3.8	129
171	Serotonergic Intervention Increases Affiliative Behavior in Humans. Annals of the New York Academy of Sciences, 1997, 807, 492-493.	3 . 8	30
172	Antiglucocorticoid treatments in psychiatry. Psychoneuroendocrinology, 1997, 22, S121-S124.	2.7	38
173	MANAGEMENT OF TREATMENT-RESISTANT UNIPOLAR AND CHRONICALLY DEPRESSED PATIENTS. Psychiatric Clinics of North America, 1996, 19, 201-213.	1.3	6
174	A complete genome screen for genes predisposing to severe bipolar disorder in two Costa Rican pedigrees. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 13060-13065.	7.1	161
175	Mood management and nicotine gum in smoking treatment: A therapeutic contact and placebo-controlled study Journal of Consulting and Clinical Psychology, 1996, 64, 1003-1009.	2.0	170
176	Use of linkage disequilibrium approaches to map genes for bipolar disorder in the Costa Rican population. American Journal of Medical Genetics Part A, 1996, 67, 244-253.	2.4	69
177	Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. Nature Genetics, 1996, 12, 436-441.	21.4	246
178	Attitudes towards bipolar disorder and predictive genetic testing among patients and providers Journal of Medical Genetics, 1996, 33, 544-549.	3.2	66
179	Use of linkage disequilibrium approaches to map genes for bipolar disorder in the Costa Rican population. American Journal of Medical Genetics Part A, 1996, 67, 244-253.	2.4	1
180	Mood and depression diagnosis in smoking cessation Experimental and Clinical Psychopharmacology, 1995, 3, 389-395.	1.8	103

#	Article	IF	CITATIONS
181	Antidepressant and Cognitionâ€Enhancing Effects of DHEA in Major Depression. Annals of the New York Academy of Sciences, 1995, 774, 337-339.	3.8	80
182	Are Stress Hormones and Serotonin Related to Aggression in Primates?. Archives of General Psychiatry, 1994, 51, 72.	12.3	0
183	Dehydroepiandrosterone (DHEA) and memory in depressed patients. Biological Psychiatry, 1994, 35, 642.	1.3	4
184	Antiglucocorticoid medication effects on specific depressive symptoms. Biological Psychiatry, 1994, 35, 678-679.	1.3	3
185	Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers Journal of Consulting and Clinical Psychology, 1994, 62, 141-146.	2.0	247
186	Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers Journal of Consulting and Clinical Psychology, 1994, 62, 141-146.	2.0	140
187	Steroid modulation of human memory: Biochemical correlates. Biological Psychiatry, 1993, 33, 744-746.	1.3	34
188	Ketoconazole administration in hypercortisolemic depression. American Journal of Psychiatry, 1993, 150, 810-812.	7.2	124
189	Mind and brain. Science, 1993, 262, 1629-1629.	12.6	2
190	Nicotine, negative affect, and depression Journal of Consulting and Clinical Psychology, 1993, 61, 761-767.	2.0	248
191	Nicotine, negative affect, and depression Journal of Consulting and Clinical Psychology, 1993, 61, 761-767.	2.0	130
192	Rational Polypharmacy in the Treatment of Mood Disorders. Annals of Clinical Psychiatry, 1993, 5, 91-100.	0.6	18
193	Behavioral Side Effects of Corticosteroid Therapy. Psychiatric Annals, 1993, 23, 703-708.	0.1	13
194	Subcortical Dementia. American Journal of Psychiatry, 1992, 149, 1271-1271.	7.2	1
195	Benzodiazepine responsivity in schizophrenia. Schizophrenia Research, 1991, 4, 296.	2.0	1
196	MRI Deep white matter hyperintensity in a psychiatric population. Biological Psychiatry, 1991, 29, 918-922.	1.3	29
197	Society, Stress, and Disease, vol. 5: Old Age. American Journal of Psychiatry, 1991, 148, 804-804.	7.2	0
198	Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects. American Journal of Psychiatry, 1991, 148, 1251-1251.	7.2	0

#	Article	IF	Citations
199	Pineal-adrenal interactions: The effect of acute pharmacological blockade of nocturnal melatonin secretion. Psychiatry Research, 1990, 32, 183-189.	3.3	24
200	Newton's Madness: Further Tales of Clinical Neurology. American Journal of Psychiatry, 1990, 147, 1682-1683.	7.2	0
201	Bipolar Disorder in a Six-Year-Old Boy: A Diagnosis by Proxy. Journal of the American Academy of Child and Adolescent Psychiatry, 1988, 27, 133-137.	0.5	4
202	Cortisol and Behaviorally Conditioned Histamine Release. Annals of the New York Academy of Sciences, 1987, 496, 583-587.	3.8	17
203	Neuroleptic dose: A statistical model for analyzing historical trends. Journal of Psychiatric Research, 1987, 21, 199-214.	3.1	4
204	Behavioral Disturbances Associated with Endocrine Disorders. Annual Review of Medicine, 1986, 37, 205-214.	12.2	32
205	Frontiers in Biochemical and Pharmacological Research in Depression: Advances in Biochemical Psychopharmacology, vol. 39. American Journal of Psychiatry, 1986, 143, 665-665.	7.2	0
206	A neuroanatomic perspective on state-dependent learning: The role of the striatum. Acta Neurologica Scandinavica, 1986, 74, 31-36.	2.1	4
207	Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients. Psychopharmacology, 1985, 87, 59-63.	3.1	13
208	Habituation and cortisol dysregulation in depression. Biological Psychiatry, 1985, 20, 980-989.	1.3	26
209	Psychiatric symptoms in Behçet's syndrome. Psychosomatics, 1985, 26, 547-549.	2.5	14
210	Evidence for physiological effects of hypercortisolemia in psychiatric patients. Psychiatry Research, 1985, 14, 47-56.	3.3	23
211	Sex differences and asymmetries of catecholamines: Relation to turning preferences. Pharmacology Biochemistry and Behavior, 1984, 20, 327-330.	2.9	16
212	Hormonal mediation of the memory disorder in depression. Drug Development Research, 1984, 4, 489-500.	2.9	36
213	Electrophysiologic abnormalities in patients with eating disorders. Comprehensive Psychiatry, 1984, 25, 216-224.	3.1	13
214	Plasma î°,-tryptophan/neutral amino acid ratio and dexamethasone suppression in depression. Psychiatry Research, 1984, 11, 185-192.	3.3	59
215	Effects of Two Doses of Methylphenidate on Verbal Information Processing in Hyperactive Children. Journal of Clinical Psychopharmacology, 1984, 4, 82-87.	1.4	25
216	Methodology in Evaluation of Psychiatric Treatment. American Journal of Psychiatry, 1984, 141, 1297-1297.	7.2	1

#	Article	IF	CITATIONS
217	Regulation of ACTH and cortisol in depression. Peptides, 1983, 4, 785-788.	2.4	35
218	Hyperthyroidism May Affect Dexamethasone Suppression. Journal of Clinical Psychopharmacology, 1983, 3, 203.	1.4	0
219	Prevention and Treatment of Depression. American Journal of Psychiatry, 1983, 140, 124-125.	7.2	0
220	Cognitive Changes in Schizoaffective Patients. Archives of General Psychiatry, 1983, 40, 1255.	12.3	4
221	ROLE OF OPIOID PEPTIDES IN DISORDERS OF ATTENTION IN PSYCHPATHOLOGY. Annals of the New York Academy of Sciences, 1982, 398, 352-365.	3.8	8
222	Neuropeptide modulation of opiate and ethanol tolerance and dependence. Medical Hypotheses, 1980, 6, 1141-1148.	1.5	6
223	Effect of lithium carbonate on memory processes of bipolar affectively ill patients. Psychopharmacology, 1979, 63, 39-42.	3.1	48
224	Behavioral Side Effects of Medical Drugs. Primary Care - Clinics in Office Practice, 1979, 6, 283-294.	1.6	1
225	Use of in vivo consultation in dyadic psychotherapy Psychotherapy, 1976, 13, 193-195.	1.2	0
226	Neuropsychiatric Effects of Dehydroepiandrosterone (DHEA). , 0, , .		4